阿卡波糖对比磺脲类作为二甲双胍附加治疗的心血管获益
本研究利用台湾糖尿病论质计酬计划数据库,采用倾向评分匹配队列设计,比较2型糖尿病患者在二甲双胍基础上加用阿卡波糖(14,306例)或磺脲类(196,143例)的临床结局。匹配后每组14,306例,中位随访期间阿卡波糖组主要动脉粥样硬化事件住院、缺血性卒中住院及低血糖住院风险均显著低于磺脲类组。
要点
- 二甲双胍基础上加用阿卡波糖较加用磺脲类,主要动脉粥样硬化事件住院风险显著降低(HR 0.69)。
- 阿卡波糖组缺血性卒中住院风险显著低于磺脲类组(HR 0.68)。
- 阿卡波糖组低血糖住院风险显著低于磺脲类组(HR 0.23)。
核心结论
- 在2型糖尿病治疗中,二甲双胍基础上加用阿卡波糖较加用磺脲类与主要动脉粥样硬化事件、缺血性卒中及低血糖住院风险降低相关。
研究设计与样本
- 倾向评分匹配队列研究,数据来自台湾糖尿病论质计酬计划数据库,2004至2015年接受二甲双胍治疗并加用磺脲类(196,143例)或阿卡波糖(14,306例)的2型糖尿病患者。
- 共纳入14,306对倾向评分匹配患者(年龄55.8 ± 13.1岁;男性47.8%),随访全因死亡及主要动脉粥样硬化事件(心肌梗死和缺血性卒中)、心力衰竭或低血糖住院等临床不良事件。
主要发现
- 与加用磺脲类相比,加用阿卡波糖与主要动脉粥样硬化事件住院风险显著降低相关(HR 0.69;95% CI 0.52至0.91)。
- 与加用磺脲类相比,加用阿卡波糖与缺血性卒中住院风险显著降低相关(HR 0.68;95% CI 0.49至0.94)。
- 与加用磺脲类相比,加用阿卡波糖与低血糖住院风险显著降低相关(HR 0.23;95% CI 0.08至0.71)。
临床怎么用
- 在2型糖尿病患者以二甲双胍为基础治疗时,选择加用阿卡波糖而非磺脲类可能与较低的主要动脉粥样硬化事件、缺血性卒中及低血糖住院风险相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Although α-glucosidase inhibitors (AGIs) have been shown to reduce the risk of myocardial infarction in patients with impaired glucose tolerance, the cardiovascular benefits of AGIs in those with type 2 diabetes (T2D) remains unclear. OBJECTIVE: We compared the clinical outcomes of adding acarbose vs sulfonylureas to metformin therapy in patients with T2D. DESIGN, SETTING, AND PARTICIPANTS: The study population was drawn from the database of the Diabetes Pay-for-Performance program in Taiwan. Sulfonylureas and acarbose were prescribed to 196,143 and 14,306 patients with T2D, respectively, from 2004 to 2015, who had been treated with metformin. A propensity score-matched cohort study was conducted. The patients were followed up for clinical adverse events of all-cause mortality and hospitalizations of major atherosclerotic events (i.e., myocardial infarction and ischemic stroke), heart failure, or hypoglycemia. RESULTS: A total of 14,306 propensity score-matched pairs (age, 55.8 ± 13.1 years; 47.8% men) were enrolled in the present analysis. Compared with sulfonylureas as the add-on therapy to metformin, the use of acarbose was associated with significantly lower risks of hospitalizations for major atherosclerotic events [hazard ratio (HR), 0.69; 95% CI, 0.52 to 0.91], ischemic stroke (HR, 0.68; 95% CI, 0.49 to 0.94), and hypoglycemia (HR, 0.23; 95% CI, 0.08 to 0.71), after accounting for major confounding factors. CONCLUSIONS: In T2D treatment, the use of acarbose as an add-on remedy to metformin was associated with lower risks of major atherosclerotic events, ischemic stroke, and hypoglycemia compared with the use of sulfonylurea as an add-on remedy.
引用
- Hsu PF, Sung SH, Cheng HM, et al. Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin. J Clin Endocrinol Metab. 2018. PMID: 30113697. doi:10.1210/jc.2018-00040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。